默克集团（Merck Group）著名的制药市场参与者，总部位于德国达姆施塔特（Darmstadt），最近与F-Star（一家英国生物技术公司F-Star）合作，该公司开发了免疫肿瘤学抗体疗法。爱游戏登陆根据该协议，默克获得了开发和商业化其五种双特异性抗癌抗体的权利。

这项合作需要默克公司预先支付1.3亿美元（约1.15亿欧元），其中包括最初两年的里程碑付款和研发资金。根据报道，该协议基本上是通过F-Star的双特异性抗体平台来帮助默克的I-O平台。由于默克公司仍然保留从新兴生物技术公司F-Star收购计划的选择，因此它很可能价值超过10亿欧元。

Merck, the reputed pharmaceutical & biotechnology environmental monitoring market player, through this deal with F-Star, will have the privilege of holding the exclusive development and commercialization rights to the latter’s preclinical lead asset, the FS118, which is designed to block the Programmed Death-Ligand 1 (PD-L1) and Lymphocyte-Activation Gene 3 (LAG-3), both of which are the pathways that are normally used by cancer cells to deceive the human immune system. F-Star had earlier conducted a preclinical model, in which the company demonstrated the efficiency of FS118 in comparison with other monotherapy combinations.

One of the top officials of the former Fierce 15 winner was quoted stating that this multimillion euro deal will accentuate the efficacy of its asset-centric model, which will maximize the value of the company’s bispecific programs and technology platform, in addition to establishing a flexible framework for conducting potential deals. Furthermore, this approach will also provide F-Star with sufficient capital to continue the research and development activities on its own pipeline of bispecific antibodies, focusing on immuno-oncology.

默克对这笔交易的建议同样满意。默克公司的高管表示，与F-Star的这项合作将有助于该公司即兴创作双特异性免疫疗法的现有投资组合。此外，该交易将弹射默克在全球科学研发服务市场中的地位。

F-Star与默克的长期联系将通过这项协定加强。根据官方声明，F-Star的愿景致力于改变癌症的治疗方法，它旨在通过与默克公司合作并允许其商业化FS118和其他下一代免疫肿瘤学化合物来实现。

与默克公司的这笔交易是在F-Star Delta内举行的，F-Star的4^Th以资产为中心的车辆。邮政获取数据包（预定义），默克公司还可以接管F-Star Delta并获取双特异性程序。为了实现同样的价格，默克公司可能会付出额外的付款，以增加交易价值，从而使其超过10亿欧元。